Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors (Q85169133)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20927639%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

title

Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20927639%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

1 reference

1 reference

Laura Vidal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20927639%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Margarita Magem

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20927639%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Clare Barlow

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20927639%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Beatriz Pardo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20927639%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Amalia Florez

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20927639%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Ana Montes

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20927639%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Margarita Garcia

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20927639%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Ian Judson

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20927639%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Claudia Lebedinsky

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20927639%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Stan B Kaye

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20927639%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Ramón Salazar

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20927639%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

publication date

7 October 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20927639%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

15 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20927639%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20927639%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20927639%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

page(s)

616-628

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20927639%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10637-010-9559-3

15 February 2020

exact match

0 references

cites work

Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules

1 reference

12 December 2020

Platinum resistance: the role of DNA repair pathways

1 reference

12 December 2020

Clinical development of platinum complexes in cancer therapy: an historical perspective and an update.

1 reference

12 December 2020

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

12 December 2020

Quantitative determination of Ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry

1 reference

12 December 2020

Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours

1 reference

12 December 2020

Effect of prednisone on renal function in man

1 reference

12 December 2020

Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology

1 reference

12 December 2020

Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma

1 reference

12 December 2020

Mapping the literature: role of trabectedin as a new chemotherapy option in advanced pretreated soft tissue sarcoma

1 reference

12 December 2020

Determination of the glomerular filtration rate (GFR): methodological problems, age-dependence, consequences of various surgical interventions, and the influence of different drugs and toxic substances

1 reference

12 December 2020

A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies

1 reference

12 December 2020

2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel

1 reference

12 December 2020

DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata

1 reference

12 December 2020

New-generation platinum agents for solid tumors

1 reference

12 December 2020

Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours.

1 reference

12 December 2020

Antitumor activity- and gene expression-based profiling of ecteinascidin Et 743 and phthalascidin Pt 650.

1 reference

12 December 2020

Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group

1 reference

12 December 2020

Targeting DNA repair as a promising approach in cancer therapy

1 reference

12 December 2020

Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.

1 reference

12 December 2020

Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study.

1 reference

12 December 2020

Phase II Study of Trabectedin in Pretreated Patients with Advanced Colorectal Cancer

1 reference

12 December 2020

The combination of yondelis and cisplatin is synergistic against human tumor xenografts

1 reference

12 December 2020

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

1 reference

12 December 2020

Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways

1 reference

12 December 2020

Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer

1 reference

12 December 2020

A phase II study of gemcitabine plus carboplatin in platinum-sensitive, recurrent ovarian carcinoma

1 reference

12 December 2020

Unique features of the mode of action of ET-743.

1 reference

12 December 2020

Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove

1 reference

12 December 2020